Scholarlink

Background <p>Delirium is a common and distressing symptom in patients with cancer, while opioids—which are essential in managing cancer pain—can cause delirium. Opioid switching is a widely used strategy for the management of opioid-induced delirium; however, its efficacy is yet to be verified. This systematic review aimed to determine opioid switching’s efficacy and safety for managing opioid-induced delirium in patients with cancer.</p> Methods <p>This systematic review was conducted in accordance with the PRISMA guidelines. We searched four databases (PubMed, Cochrane Controlled Register of Trials, Cochrane Library, and Ichishi-Web) on September 6, 2023, with an updated PubMed search on October 20, 2024. Our review included studies on opioid switching for managing delirium in patients with cancer. If there were less than two randomized controlled trials (RCTs), we included observational studies. Data extraction and evaluation were independently conducted by two reviewers using the GRADE evaluation. The study protocol was registered (UMIN000051787).</p> Results <p>The literature search identified seven observational studies without a control group; however, no RCTs were found. Four observational studies reported improvements in the severity of delirium symptoms. No study reported worsening pain or dyspnea after opioid switching. According to the GRADE framework, all outcomes were graded very low on certainty.</p> Conclusions <p>Although observational studies imply opioid switching’s effectiveness for managing opioid-induced delirium in patients with cancer, there is a lack of RCTs and the level of evidence is very low. Thus, RCTs are warranted to confirm opioid switching’s efficacy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Opioid switching to improve delirium symptoms in patients with cancer: a systematic review

  • 期刊论文

  • 发表日期：

    2025年8月13日

查看全文
  • Kousuke Yamanaka,
  • Takaaki Hasegawa,
  • Yoshinobu Matsuda,
  • Shinichiro Inoue,
  • Hitoshi Tanimukai,
  • Saho Wada,
  • Jun Kako,
  • Yoshinobu Matsuda,
  • Shinichiro Inoue,
  • Jun Kako,
  • Hitoshi Tanimukai,
  • Saho Wada,
  • Tetsuro Ishida,
  • Tetsuya Ito,
  • Shuji Inada,
  • Nozomu Oya,
  • Akiharux Okamoto,
  • Yoshiaki Okamoto,
  • Yusuke Kanno,
  • Yuuichi Kitaura,
  • Masamitsu Kobayashi,
  • Yoshinori Saeki,
  • Kaori Shinsato,
  • Koji Sugano,
  • Mari Takeuchi,
  • Kazuyuki Niki,
  • Takaaki Hasegawa,
  • Saki Harashima,
  • Takatoshi Hirayama,
  • Takafumi Miyoshi,
  • Shuntaro Yasuda,
  • Kousuke Yamanaka,
  • Yoshihiro Yamamoto,
  • Masafumi Yoshimura

摘要

Background

Delirium is a common and distressing symptom in patients with cancer, while opioids—which are essential in managing cancer pain—can cause delirium. Opioid switching is a widely used strategy for the management of opioid-induced delirium; however, its efficacy is yet to be verified. This systematic review aimed to determine opioid switching’s efficacy and safety for managing opioid-induced delirium in patients with cancer.

Methods

This systematic review was conducted in accordance with the PRISMA guidelines. We searched four databases (PubMed, Cochrane Controlled Register of Trials, Cochrane Library, and Ichishi-Web) on September 6, 2023, with an updated PubMed search on October 20, 2024. Our review included studies on opioid switching for managing delirium in patients with cancer. If there were less than two randomized controlled trials (RCTs), we included observational studies. Data extraction and evaluation were independently conducted by two reviewers using the GRADE evaluation. The study protocol was registered (UMIN000051787).

Results

The literature search identified seven observational studies without a control group; however, no RCTs were found. Four observational studies reported improvements in the severity of delirium symptoms. No study reported worsening pain or dyspnea after opioid switching. According to the GRADE framework, all outcomes were graded very low on certainty.

Conclusions

Although observational studies imply opioid switching’s effectiveness for managing opioid-induced delirium in patients with cancer, there is a lack of RCTs and the level of evidence is very low. Thus, RCTs are warranted to confirm opioid switching’s efficacy.